CN118215476A - 用于抑制或预防内耳性耳聋的含有麦角硫因的组合物 - Google Patents

用于抑制或预防内耳性耳聋的含有麦角硫因的组合物 Download PDF

Info

Publication number
CN118215476A
CN118215476A CN202280074409.0A CN202280074409A CN118215476A CN 118215476 A CN118215476 A CN 118215476A CN 202280074409 A CN202280074409 A CN 202280074409A CN 118215476 A CN118215476 A CN 118215476A
Authority
CN
China
Prior art keywords
ergothioneine
composition
deafness
administration
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280074409.0A
Other languages
English (en)
Chinese (zh)
Inventor
樋田匠
莪山真与
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Gas Chemical Co Inc
Original Assignee
Mitsubishi Gas Chemical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Gas Chemical Co Inc filed Critical Mitsubishi Gas Chemical Co Inc
Publication of CN118215476A publication Critical patent/CN118215476A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/14—Yeasts or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Volume Flow (AREA)
CN202280074409.0A 2021-11-08 2022-10-19 用于抑制或预防内耳性耳聋的含有麦角硫因的组合物 Pending CN118215476A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-181678 2021-11-08
JP2021181678 2021-11-08
PCT/JP2022/038850 WO2023079954A1 (ja) 2021-11-08 2022-10-19 内耳性難聴の抑制又は予防のためのエルゴチオネインを含む組成物

Publications (1)

Publication Number Publication Date
CN118215476A true CN118215476A (zh) 2024-06-18

Family

ID=86240934

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280074409.0A Pending CN118215476A (zh) 2021-11-08 2022-10-19 用于抑制或预防内耳性耳聋的含有麦角硫因的组合物

Country Status (6)

Country Link
US (1) US20250108037A1 (https=)
EP (1) EP4431095A4 (https=)
JP (1) JPWO2023079954A1 (https=)
CN (1) CN118215476A (https=)
TW (1) TW202327585A (https=)
WO (1) WO2023079954A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118319905A (zh) * 2024-04-24 2024-07-12 中国药科大学 麦角硫因在制备预防和降低耳损伤和改善听力药物的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009249356A (ja) * 2008-04-08 2009-10-29 Daicel Chem Ind Ltd エルゴチオネインの製造方法
JP5421366B2 (ja) 2008-07-21 2014-02-19 オトノミ―，インク． 制御放出性の耳の構造体調節および生来の免疫システム調節化合物および耳の障害の処置のための方法
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
JP5548839B2 (ja) * 2009-08-08 2014-07-16 国立大学法人名古屋大学 難聴又は耳鳴りの予防・治療剤
JP2014223051A (ja) * 2012-07-13 2014-12-04 タカラバイオ株式会社 エルゴチオネインの製造方法
US9437472B2 (en) * 2014-02-27 2016-09-06 Taiwan Semiconductor Manufacturing Company Ltd. Semiconductor line feature and manufacturing method thereof
US11390897B2 (en) * 2014-12-22 2022-07-19 National University Corporation Okayama University Method for producing ergothioneine
WO2017117701A1 (zh) * 2016-01-04 2017-07-13 葡萄王生技股份有限公司 预防听力退化的活性物质、含其的组合物、及其制备方法
JP6758703B2 (ja) * 2016-06-21 2020-09-23 国立大学法人 岡山大学 エルゴチオネインの産生方法
JP7033789B2 (ja) * 2016-06-29 2022-03-11 オトノミー，インク． トリグリセリド耳用製剤とその使用
JP7529255B2 (ja) * 2019-10-17 2024-08-06 株式会社エル・エスコーポレーション 認知機能速度改善用の組成物
JP6864131B1 (ja) * 2020-03-04 2021-04-28 長瀬産業株式会社 Ｌ−エルゴチオネイン含有組成物

Also Published As

Publication number Publication date
EP4431095A4 (en) 2025-03-26
JPWO2023079954A1 (https=) 2023-05-11
TW202327585A (zh) 2023-07-16
EP4431095A1 (en) 2024-09-18
WO2023079954A1 (ja) 2023-05-11
US20250108037A1 (en) 2025-04-03

Similar Documents

Publication Publication Date Title
US12336974B2 (en) Methods and compositions for preventing and treating auditory dysfunctions
Mielke et al. Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1β production
Agterberg et al. Enhanced survival of spiral ganglion cells after cessation of treatment with brain-derived neurotrophic factor in deafened guinea pigs
EP1471902B1 (en) Compositions for use in methods for treating hearing loss
Gersten et al. Ototoxicity and platinum uptake following cyclic administration of platinum-based chemotherapeutic agents
CA2466869C (en) Methods and compositions for ameliorating the undesirable effects of chemotherapy
WO1998010757A9 (en) The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity
DE2710327B2 (de) Verwendung von Benzaldehyd
CN118215476A (zh) 用于抑制或预防内耳性耳聋的含有麦角硫因的组合物
US11517554B2 (en) Method for preventing or treating Alzheimer's disease
EP4699612A1 (en) Proliferation inhibitor for periodontal disease bacterium and application for same
RU2197984C1 (ru) Способ лечения различных форм туберкулеза легких, в том числе резистентных к противотуберкулезной химиотерапии
KR101901412B1 (ko) 적포도잎 추출물을 유효성분으로 함유하는 난청의 예방 또는 치료용 조성물
JPH05509309A (ja) ２―フェニル―１，２―ベンズイソセレナゾール―３（２ｈ）―オンの利用法
WO2002096414A1 (de) Arzneimittel enthaltend einen effektor des glutathionmetabolismus zusammen mit alpha-liponsäure im rahmen der nierenersatztherapie
EP4545066A2 (en) 4-phenyl-tetrahydropyridine derivatives for treating hearing diseases
AU2021221333B2 (en) Novel medicament for treating inflammatory disease
KR101891395B1 (ko) 시스플라틴에 의한 이독성의 예방 또는 치료용 약학적 조성물
WO2024023710A1 (en) Tafamidis pharmaceutical compositions
CN116115730A (zh) 枸杞糖肽在制备预防或治疗药物性耳聋的药物中的用途
US20160022663A1 (en) Local cochlear application of statins for stimulating neurite regrowth in the cochlea
CN113876712A (zh) 一种奥沙利铂脂质体及其注射剂在制备治疗胃癌药物中的用途
CN101264054A (zh) 利福霉素钠注射液及其制备方法
CN104922677A (zh) 一种含盐酸千金藤碱的药物组合物在制备治疗白细胞减少的药物中的应用
EP0476391A2 (en) Anti-AIDS virus composition containing cepharanthine as active compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination